Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- The Rosen Law Firm PACAPR IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- AcroMeta to Enter Ambient Temperature Cellular Logistics Through Strategic Partnership with Macro HRD SG Pte. Ltd.AcroMeta to acquire a strategic stake in Macro-ATCLS Pte. Ltd., for the Ambient Temperature Cellular Logistics business. Option to acquire an exclusive licence to deploy the Ambient Temperature Cellular Logistics platform across Southeast Asia. The Group will continue to evaluate strategic opportunities that support its long-term growth. [L-R] Signing ceremony between Mr Toh Ker How, Executive Director of AcroMeta Group Limited, and Ms Kawinyarat Mardpiratchata, CFO and Managing Partner of Macro-HRD Pte. Ltd. SINGAPORE, Sept 7, 2026 - AcroMeta Group Limited (“AcroMeta”, or the “Company”, and together with its subsidiaries, the “Group”) today announced that it has entered into a non-binding term sheet (“Term Sheet”) with Macro HRD SG Pte. Ltd. (“Macro”), a Singapore-based provider of management consultancy services to the healthcare sector. The Term Sheet sets out the principal terms for a strategic partnership between AcroMeta and Macro-ATCLS Pte. Ltd. (“Macro-ATCLS”), the company through which Macro’s Ambient Temperature Cellular Logistics technology is being commercialised. Mr Lawrence Toh, Executive Director of AcroMeta Group Limited, said, “This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we’re excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia.” About Ambient Temperature Cellular Logistics (ATCLS) Ambient Temperature Cell Logistics (ATCLS) is an emerging technology licensed by Macro HRD, designed to fundamentally transform the transportation and distribution of living cells and other temperature-sensitive biological materials by eliminating reliance on conventional refrigerated and cryogenic cold chains. ATCLS uses proprietary ambient-temperature preservation and reactivation technologies, supported by its proprietary Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance, chain-of-identity and process control, enabling dormant living cells to be transported at ambient temperature and reactivated at the point of use. The opportunity addresses rapidly expanding markets including stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, organ and tissue transplantation, and cell-and-gene-therapy logistics; the underlying markets cited in the project materials range from US$5.2 billion for immune-cell therapy to US$47 billion for organ transplantation, while the global cell-and-gene-therapy 3PL market is estimated at US$1.81 billion in 2025 and projected to reach US$16.95 billion by 2035 (25.1% CAGR). Based on defined ambient-addressable segments, ATCLS estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032, positioning the technology as a potential category-creating solution capable of reducing the cost, fragility and geographic limitations of conventional cold-chain logistics. (See Footnote 1) Proposed Exclusive Licensing Arrangement for Southeast Asia AcroMeta will have an option to acquire an exclusive licence to deploy the ATCLS technology across agreed territories in Southeast Asia, including the right to appoint sub-licensees. The proposed exclusive licensing arrangement is intended to provide AcroMeta with the rights to develop and commercialise the ATCLS business within Southeast Asia. This structure allows AcroMeta to secure exclusive rights across the Southeast Asian markets, together with a first right to acquire additional territories, significantly expanding the Group’s potential commercial reach for the ATCLS technology. Building AcroMeta’s Platform Growth Strategy The Group intends to continue evaluating strategic opportunities to support its long-term value creation for shareholders. The Board remains focused on disciplined capital allocation as the Group progresses through its next phase of development. Footnote 1: This information was provided by Macro's management and has not been verified by the board of directors. The directors have not audited or verified the data supplied by the company. About AcroMeta Group Limited (SGX: 43F) AcroMeta Group Limited (“AcroMeta” or the “Company”, and together with its subsidiaries, the “Group”), is in the business of facility management services. The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.AcroMeta.com. About Macro HRD SG Pte. Ltd. (Macro HRD) Macro HRD is a Singapore-based biotechnology and therapeutics company established in 2024, focused on developing scalable, precision-medicine solutions for high-burden infectious diseases with significant unmet medical needs. The company integrates advanced biology, therapeutic platform technologies and AI/ML-enabled decision systems to accelerate drug discovery and translational development from scientific research through clinical application. Its development portfolio includes innovative approaches targeting HIV/AIDS, HPV and other enveloped viruses, supported by proprietary therapeutic and drug-delivery platforms. Macro HRD brings together an international network of scientific, clinical, regulatory, investment and technology expertise, with the mission of translating breakthrough science into novel therapeutics with meaningful global healthcare impact. Media and Analysts Contact: Waterbrooks Consultants Pte Ltd Mr Wayne Koo Tel: +65 9338 8166 / +65 8901 9780 Email: [email protected] Email: [email protected]
- Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 BillionSHANGHAI, Sep 7, 2026 - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) today announced an H share repurchase plan, under which the company intends to repurchase its H shares with an aggregate amount of up to HK$1 billion. The shares so repurchased will be cancelled or held as treasury shares. Taking concrete action to respond to market concerns, this repurchase plan demonstrates management's unwavering confidence in the company's intrinsic value. The plan has come into effect and will be implemented as soon as practicable. As a continuation of the Group's long-term value management toolkit, the company will dynamically evaluate and execute repurchases on a rolling basis in response to market conditions, establishing a normalized mechanism for shareholder returns. In the first half of 2026, Fosun Pharma's earnings quality continued to improve, with revenue contributions from innovative drugs and international markets steadily increasing. Core operational indicators further consolidated upon the foundation of 2025: - Revenue: RMB 20,442 million, up 4.75% year-on-year;- Profit attributable to shareholders of the listed company, net of non-recurring gains and losses: RMB 1,144 million, up 19.09% year-on-year;- Net cash generated from operating activities: RMB 2,424 million, up 13.59% year-on-year. The repurchase will be primarily funded by proceeds from the disposal of approximately 6.00% equity interest in Gland Pharma, with total consideration of around US$294 million. Upon completion of the transaction, Fosun Pharma remains the promoter of Gland Pharma with an approximate 45.76% equity interest, and Gland Pharma will continue to be consolidated into Fosun Pharma's financial statements. Net proceeds from the transaction will primarily be allocated toward the Company's R&D investments, share repurchases, and the repayment of interest-bearing debts. As the controlling shareholder, Fosun Pharma remains fully confident in Gland Pharma's long-term development and its enduring role as a key engine for overseas value creation. Looking ahead, Fosun Pharma will stay focused on innovation and globalization, accelerating the R&D progress and commercialization of its major pipeline candidates. This repurchase program is intended to convey the Company’s confidence in its intrinsic value and to generate sustainable returns for shareholders. About Fosun Pharma Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem. Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia. Looking ahead, guided by the strategy of “Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health. For more information about the Group, please visit the company website:https://www.fosunpharma.com/en/
- 復星醫藥宣佈擬以不超過10億港元回購H股 持續回饋股東Companies: Fosun International Limited上海, 2026年9月7日 - 9月6日，復星醫藥宣佈H股回購方案， 計劃以不超過10億港元總金額回購H股股份 ，回購股份將註銷或作為庫存股持有。本次回購方案以實際行動回應市場關切，彰顯公司管理層對公司內在價值的堅定信心，該方案已生效並將於即日起盡快推進實施。該計劃亦為公司長期價值管理工具的延續運用，後續公司將結合市場情況動態評估、滾動實施，形成常態化股東回報機制。 2026年上半年，復星醫藥盈利質量持續向好，創新藥品與海外收入佔比穩步提升，核心經營指標在2025年基礎上進一步夯實。 - 營業收入 ：204.42億元，同比增長 4.75%； - 扣非歸母淨利潤 ：11.44億元，同比增長 19.09%； - 經營性現金流 ：24.24億元，同比增長 13.59%。 本次回購資金主要來源於減持Gland Pharma約6.00%股份所得（交易總對價約2.94億美元）。交易完成後，復星醫藥仍為Gland Pharm
- 復星醫藥宣佈擬以不超過10億港元回購H股 持續回饋股東Companies: Fosun International Limited上海, 2026年9月7日 - 9月6日，復星醫藥宣佈H股回購方案，計劃以不超過10億港元總金額回購H股股份，回購股份將註銷或作為庫存股持有。本次回購方案以實際行動回應市場關切，彰顯公司管理層對公司內在價值的堅定信心，該方案已生效並將於即日起盡快推進實施。該計劃亦為公司長期價值管理工具的延續運用，後續公司將結合市場情況動態評估、滾動實施，形成常態化股東回報機制。 2026年上半年，復星醫藥盈利質量持續向好，創新藥品與海外收入佔比穩步提升，核心經營指標在2025年基礎上進一步夯實。 - 營業收入：204.42億元，同比增長 4.75%； - 扣非歸母淨利潤：11.44億元，同比增長 19.09%； - 經營性現金流：24.24億元，同比增長 13.59%。 本次回購資金主要來源於減持Gland Pharma約6.00%股份所得（交易總對價約2.94億美元）。交易完成後，復星醫藥仍為Gland Pharma控股股東，持股約45.76%，Gland Pharma仍納入復星醫藥合併報表子公司範圍；交易回籠資金將主要用於集團研發投入、股份回購、償還帶息債務等。作為第一大股東，復星醫藥對Gland的長期發展充滿信心，其將持續發揮海外價值驅動引擎作用。 展望未來，復星醫藥將繼續聚焦創新與全球化，加速重磅品種研發與產業化進程。本次回購旨在堅定傳遞價值信心，為股東創造持續回報。 關於復星醫藥 復星醫藥（股票代碼：600196.SH；02196.HK）成立於1994年，是一家創新驅動的全球化醫藥健康產業集團。我們以「讓每個家庭樂享健康」為使命，深耕製藥業務，以創新藥為發展重點，直接運營醫療器械與醫學診斷、醫療健康服務業務，並通過聯營公司國藥控股覆蓋醫藥商業領域，構建醫藥健康全產業鏈生態。 聚力創新，深耕全球。復星醫藥已形成開放式、全球化的創新研發體系，圍繞未滿足臨床需求，深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域，積極拓展慢病及罕見病等領域，打造具有長期競爭力的產品管線與綜合解決方案。同時，復星醫藥持續夯實抗體和ADC、小分子、細胞治療等核心技術平台，並積極拓展核藥、小核酸等前沿技術，強化早期創新能力，加速科研成果轉化。我們的創新產品已在全球90多個國家和地區銷售，覆蓋中國、美國、歐洲、非洲、印度及東南亞等市場。 面向未來，在「創新引領、深度國際化、全面擁抱AI」的戰略引領下，復星醫藥將秉持「關愛生命、不斷創新、精益求精、合作共贏」的核心價值觀，致力於成為全球領先的醫療創新整合者，努力推動醫療創新成果惠及更多全球患者，為守護人類健康貢獻力量。 瞭解本集團更多資訊，可登錄公司網站：www.fosunpharma.com。
- Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 BillionSHANGHAI, Sep 7, 2026 - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) today announced an H share repurchase plan, under which the company intends to repurchase its H shares with an aggregate amount of up to HK$1 billion. The shares so repurchased will be cancelled or held as treasury shares. Taking concrete action to respond to market concerns, this repurchase plan demonstrates management's unwavering confidence in the company's intrinsic value. The plan has come into effect and will be implemented as soon as practicable. As a continuation of the Group's long-term value management toolkit, the company will dynamically evaluate and execute repurchases on a rolling basis in response to market conditions, establishing a normalized mechanism for shareholder returns. In the first half of 2026, Fosun Pharma's earnings quality continued to improve, with revenue contributions from innovative drugs and international markets steadily increasing. Core operational indicators further consolidated upon the foundation of 2025: - Revenue: RMB 20,442 million, up 4.75% year-on-year; - Profit attributable to shareholders of the listed company, net of non-recurring gains and losses: RMB 1,144 million, up 19.09% year-on-year; - Net cash generated from operating activities: RMB 2,424 million, up 13.59% year-on-year. The repurchase will be primarily funded by proceeds from the disposal of approximately 6.00% equity interest in Gland Pharma, with total consideration of around US$294 million. Upon completion of the transaction, Fosun Pharma remains the promoter of Gland Pharma with an approximate 45.76% equity interest, and Gland Pharma will continue to be consolidated into Fosun Pharma's financial statements. Net proceeds from the transaction will primarily be allocated toward the Company's R&D investments, share repurchases, and the repayment of interest-bearing debts. As the controlling shareholder, Fosun Pharma remains fully confident in Gland Pharma's long-term development and its enduring role as a key engine for overseas value creation. Looking ahead, Fosun Pharma will stay focused on innovation and globalization, accelerating the R&D progress and commercialization of its major pipeline candidates. This repurchase program is intended to convey the Company’s confidence in its intrinsic value and to generate sustainable returns for shareholders. About Fosun Pharma Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem. Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia. Looking ahead, guided by the strategy of “Innovation Driven, Deep Globalization, and AI Embracement”, Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health. For more information about the Group, please visit the company website: https://www.fosunpharma.com/en/
- Clover BiopharmaClover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Robust...
- Fosun PharmaFosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 BillionShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to HK$1 billion....
- AcroMeta to Enter Ambient Temperature Cellular Logistics Through Strategic Partnership with Macro HRD SG Pte. Ltd.AcroMeta to acquire a strategic stake in Macro-ATCLS Pte. Ltd., for the Ambient Temperature Cellular Logistics business. Option to acquire an exclusive licence to deploy the Ambient Temperature Cellular Logistics platform across Southeast Asia. The Group will continue to evaluate strategic opportunities that support its long-term growth. [L-R] Signing ceremony between Mr Toh Ker How, Executive Director of AcroMeta Group Limited, and Ms Kawinyarat Mardpiratchata, CFO and Managing Partner of Macro-HRD Pte. Ltd. SINGAPORE, Sept 7, 2026 - AcroMeta Group Limited (“AcroMeta”, or the “Company”, and together with its subsidiaries, the “Group”) today announced that it has entered into a non-binding term sheet (“Term Sheet”) with Macro HRD SG Pte. Ltd. (“Macro”), a Singapore-based provider of management consultancy services to the healthcare sector. The Term Sheet sets out the principal terms for a strategic partnership between AcroMeta and Macro-ATCLS Pte. Ltd. (“Macro-ATCLS”), the company through which Macro’s Ambient Temperature Cellular Logistics technology is being commercialised. Mr Lawrence Toh, Executive Director of AcroMeta Group Limited, said, “This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we’re excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia.” About Ambient Temperature Cellular Logistics (ATCLS) Ambient Temperature Cell Logistics (ATCLS) is an emerging technology licensed by Macro HRD, designed to fundamentally transform the transportation and distribution of living cells and other temperature-sensitive biological materials by eliminating reliance on conventional refrigerated and cryogenic cold chains. ATCLS uses proprietary ambient-temperature preservation and reactivation technologies, supported by its proprietary Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance, chain-of-identity and process control, enabling dormant living cells to be transported at ambient temperature and reactivated at the point of use. The opportunity addresses rapidly expanding markets including stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, organ and tissue transplantation, and cell-and-gene-therapy logistics; the underlying markets cited in the project materials range from US$5.2 billion for immune-cell therapy to US$47 billion for organ transplantation, while the global cell-and-gene-therapy 3PL market is estimated at US$1.81 billion in 2025 and projected to reach US$16.95 billion by 2035 (25.1% CAGR). Based on defined ambient-addressable segments, ATCLS estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032, positioning the technology as a potential category-creating solution capable of reducing the cost, fragility and geographic limitations of conventional cold-chain logistics. (See Footnote 1) Proposed Exclusive Licensing Arrangement for Southeast Asia AcroMeta will have an option to acquire an exclusive licence to deploy the ATCLS technology across agreed territories in Southeast Asia, including the right to appoint sub-licensees. The proposed exclusive licensing arrangement is intended to provide AcroMeta with the rights to develop and commercialise the ATCLS business within Southeast Asia. This structure allows AcroMeta to secure exclusive rights across the Southeast Asian markets, together with a first right to acquire additional territories, significantly expanding the Group’s potential commercial reach for the ATCLS technology. Building AcroMeta’s Platform Growth Strategy The Group intends to continue evaluating strategic opportunities to support its long-term value creation for shareholders. The Board remains focused on disciplined capital allocation as the Group progresses through its next phase of development. Footnote 1: This information was provided by Macro's management and has not been verified by the board of directors. The directors have not audited or verified the data supplied by the company. About AcroMeta Group Limited (SGX: 43F) AcroMeta Group Limited (“AcroMeta” or the “Company”, and together with its subsidiaries, the “Group”), is in the business of facility management services. The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.AcroMeta.com. About Macro HRD SG Pte. Ltd. (Macro HRD) Macro HRD is a Singapore-based biotechnology and therapeutics company established in 2024, focused on developing scalable, precision-medicine solutions for high-burden infectious diseases with significant unmet medical needs. The company integrates advanced biology, therapeutic platform technologies and AI/ML-enabled decision systems to accelerate drug discovery and translational development from scientific research through clinical application. Its development portfolio includes innovative approaches targeting HIV/AIDS, HPV and other enveloped viruses, supported by proprietary therapeutic and drug-delivery platforms. Macro HRD brings together an international network of scientific, clinical, regulatory, investment and technology expertise, with the mission of translating breakthrough science into novel therapeutics with meaningful global healthcare impact. Media and Analysts Contact: Waterbrooks Consultants Pte Ltd Mr Wayne Koo Tel: +65 9338 8166 / +65 8901 9780 Email: [email protected] Email: [email protected]
- Robbins Geller Rudman & Dowd LLPREGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 DeadlineRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"), have until September 14, 2026 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026 (S.D.N.Y.), the Regeneron class action...
- THE ROSEN LAW FIRM, P. A.AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud LawsuitWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration...
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.